Management of IBD Patients with Current Immunosuppressive Therapy and Concurrent Infections.


In an era of increasing use of immunomodulator therapy and biologics, opportunistic infections (OI) have emerged as a pivotal safety issue in patients with inflammatory bowel disease (IBD). Clinical studies, registries and case reports warn about the increased risk for infections, particularly OIs. Today, the challenge for a physician is not only to manage… (More)


  • Presentations referencing similar topics